Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 19/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27022333 | 0.91 | OGA (0.64) | OGA | |
| SCHEMBL20281964 | 0.80 | SMN1; SMN2 (0.74) | OGA | |
| SCHEMBL16113448 | 0.79 | SMN1; SMN2 (0.76) | OGA | |
| SCHEMBL27099904 | 0.78 | OGA (0.65) | OGA | |
| SCHEMBL27022375 | 0.77 | OGA (0.74) | OGA | |
| SCHEMBL27022369 | 0.77 | OGA (0.64) | OGA | |
| SCHEMBL18992532 | 0.77 | OGA (0.67) | OGA | |
| SCHEMBL27022374 | 0.76 | OGA (0.70) | OGA | |
| SCHEMBL20268599 | 0.76 | OGA (0.65) | OGA | |
| SCHEMBL16114197 | 0.76 | OGA (0.67) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2024-01-18 | — | — | US | disclosed |
| EP-4249475-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF | MEDIFRON DBT INC. (KR) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022108377-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF | (주) 메디프론디비티 | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018135-A1 | COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF | OGA, OGT, ENGASE | OGA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.